![BioLargo, Inc.](http://2.bp.blogspot.com/-4Eriu77Xbcw/VrZzH9bOmJI/AAAAAAAAEJc/bP7GkrBrUK8/s660/Screen%2BShot%2B2016-02-06%2Bat%2B2.26.04%2BPM.png)
BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact.
Monday 8 July 2024
New Study Confirms Forever Chemicals Are Absorbed Through Human Skin
Tuesday 2 July 2024
Chemical Makers Sue Over Rule to Rid Water of ‘Forever Chemicals’
Unsurprisingly, in the wake of new PFAS regulations, some in the industry are pushing back against the tough new treatment standards.
Great story in the New York Times on the topic: https://www.nytimes.com/2024/06/10/climate/pfas-forever-chemicals-lawsuit.html
On June 10, the New York Times reported a lawsuit by several chemical and manufacturing groups against the federal government over the per- and polyfluoroalkyl (PFAS) “Forever Chemical” drinking water standards announced by the EPA two months prior. The groups claim that the new regulations exceed the government’s authority under the Safe Drinking Water Act by requiring municipal water systems across the country to filter out some of the synthetic chemicals to near non-detectable levels.While the EPA has said that the new standard will prevent serious illness and even death for thousands of people, these groups, along with some utilities, have brought challenges against the standard, questioning the science behind it and citing the potential cost of filtering out the chemicals. The American Water Works Association and the Association of Metropolitan Water Agencies believe the EPA have “significantly underestimated” the cost for treatment plants to meet the new standards, with the EPA estimating about $1.5 billion annually to comply and utilities claiming it could cost twice that amount.
Ahead of the filing, Brenda Mallory, chair of the White House’s Council on Environmental Quality, in a public address defended the administration’s standards, stating: “Everyone should be able to turn on the tap and know that the glass of water they fill is safe to drink”. EPA officials also stated that the standard was based on the best available science and designed to be, “robust enough to withstand litigation”.
Thursday 20 June 2024
BioLargo Engineering Increases Ongoing Revenue with Another Air Force Contract
USAF work now amounts to over $100,000 in revenue per month.
Westminster, CA – June 20, 2024 – BioLargo, Inc. (OTCQX:BLGO),
a company that creates and commercializes sustainable technologies to solve
tough environmental and cleantech challenges, announced that its engineering subsidiary
has been awarded a subcontract to provide air quality services to two Arizona U.S.
Air Force bases for up to four years, with expected annual revenue of approximately
$812,000.
The news comes on the heels of a similar recently
announced contract award to serve three Air Force bases in New Mexico,
which has a potential annual average revenue of $650,000. BioLargo’s work at
the Arizona bases consists primarily of the air quality regulatory compliance
portion of a Fence-to-Fence (F2F) support contract through prime contractor HLTLI
Joint Venture, LLC, a joint venture between HL Environmental Services and TLI
Solutions.
The four-year prime contract secures pricing for F2F
services over the term of the contract but does not guarantee continuation of
the contract over that duration. In the past, BioLargo’s engineers have
continued providing services through the duration of the prime contract. In
total, BioLargo Engineering’s work at Air Force bases now amounts to over
$100,000 of revenue per month.
BioLargo Engineering, Science & Technologies President
Randall Moore commented, “We are pleased and honored to continue providing vital
engineering services to the United States Air Force and supporting their active
mission and environmental compliance needs. These new contracts will provide
for over $100,000 a month of ongoing fixed revenues while we continue to expand
our abilities to support new opportunities.”
About BioLargo, Inc.
BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences
innovator and engineering services solution provider. Our core products address
PFAS contamination, achieve advanced water and wastewater treatment, control
odor and VOCs, improve air quality, enable energy-efficiency and safe on-site
energy storage, and control infections and infectious disease. Our approach is
to invent or acquire novel technologies, develop them into product offerings,
and extend their commercial reach through licensing and channel partnerships to
maximize their impact. See our website at www.BioLargo.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include without limitation those about
BioLargo’s (the “Company”) expectations regarding anticipated revenue; and
plans for future operations. These statements involve risks and uncertainties,
and actual results may differ materially from any future results expressed or
implied by the forward-looking statements. Risks and uncertainties include without
limitation: the effect of regional economic conditions on the Company’s
business, including effects on purchasing decisions by consumers and
businesses; the ability of the Company to compete in markets that are highly
competitive and subject to rapid technological change; the ability of the
Company to manage frequent introductions and transitions of products and
services, including delivering to the marketplace, and stimulating customer
demand for, new products, services, and technological innovations on a timely
basis; the dependency of the Company on the performance of distributors of the
Company’s products. More information on these risks and other potential factors
that could affect the Company’s business and financial results is included in
the Company’s filings with the SEC, including in the “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and Results of
Operations” sections of the Company’s most recently filed periodic reports on
Form 10-K and Form 10-Q and subsequent filings. The Company assumes no
obligation to update any forward-looking statements or information, which speak
as of their respective dates.
Wednesday 12 June 2024
BioLargo Subsidiary Clyra Medical Selects Keystone Industries to Support Manufacturing of its Medical Products
Bioclynse is Clyra’s FDA 510(k) cleared, safe, highly effective, broad spectrum wound irrigation solution with enormous potential to improve patient outcomes in applications like orthopaedic surgery and dentistry. Advantages of Bioclynse include:
- Non-cytotoxic, non-sensitizing, no damage to tissue
- No rinse-out required
- Non-staining
- Sustained multi-day efficacy
- Effective against biofilms
Cary Robinson, President and CEO of
Keystone Industries, said, “We are excited to support Clyra Medical
Technologies to bring Bioclynse to the market. Keystone has a century of
experience in developing and manufacturing medical device, OTC and
pharmaceutical products. We have committed a significant investment in our
infrastructure to support the manufacturing of innovative products like Clyra’s
Bioclynse and can readily provide the needed support to scale up production
rapidly.”
Steve Harrison, President of Clyra Medical Technologies,
commented, “We are continuing to work hard and spend money to support the scaled
roll-out of the Bioclynse surgical wound irrigation solution. Finding a manufacturing
partner willing to invest significant money in new equipment and dedicated space
was critical to these efforts. We look forward to a long and mutually
prosperous relationship with Keystone.”
About BioLargo, Inc.
BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.
About Keystone Industries, Inc.
Keystone Industries is a market
leader with over 100 years experience in developing cosmetic, medical device,
OTC and pharmaceutical products. The company operates through a diverse network
of over 800 U.S. and international distribution partners in more than 70
countries. Keystone maintains FDA licensing, ISO 13485 (medical device) and
22716 certifications, as well as GMP certification and international product
registrations. Keystone’s commitment to innovation and quality ensures that the
company consistently exceed the evolving needs of their customers. See our
website at www.keystoneindustries.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include without limitation those about
BioLargo’s (the “Company”) expectations regarding anticipated revenue; and
plans for future operations. These statements involve risks and uncertainties,
and actual results may differ materially from any future results expressed or
implied by the forward-looking statements. Risks and uncertainties include without
limitation: the effect of regional economic conditions on the Company’s
business, including effects on purchasing decisions by consumers and
businesses; the ability of the Company to compete in markets that are highly
competitive and subject to rapid technological change; the ability of the
Company to manage frequent introductions and transitions of products and
services, including delivering to the marketplace, and stimulating customer
demand for, new products, services, and technological innovations on a timely
basis; the dependency of the Company on the performance of distributors of the
Company’s products. More information on these risks and other potential factors
that could affect the Company’s business and financial results is included in
the Company’s filings with the SEC, including in the “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and Results of
Operations” sections of the Company’s most recently filed periodic reports on
Form 10-K and Form 10-Q and subsequent filings. The Company assumes no
obligation to update any forward-looking statements or information, which speak
as of their respective dates.
Tuesday 11 June 2024
BioLargo Manufactures First Cellinity Battery Cells, a Safer Alternative to Lithium-ion
Westminster, CA – June 11, 2024 – BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that it had succeeded in manufacturing its first CellinityTM “Liquid Sodium” prototype battery cells. Visit www.BioLargoEnergy.com to learn more.
Cellinity is BioLargo’s next-generation battery platform designed to provide safe, environmentally conscious large-format long-duration battery energy storage for applications including grid-scale storage, renewable energy storage, charging stations for electric vehicles, and a variety of other commercial and industrial applications. Cellinity is not a lithium-ion battery – rather, it uses a unique chemistry involving molten salt electrolytes that imparts substantial benefits over lithium-ion chemistry. These newly manufactured Cellinity prototype cells will now be tested and validated for the energy storage and transfer performance claims that were generated in the technology’s early-stage research and development by its original inventors:
- Far greater safety – no runaway fires, no risk of explosion;
- Extremely long-lasting – no performance decrease over thousands of cycles;
- No self-discharging, no out-gassing, and no parasitic load for cooling;
- High energy density – more energy per unit of weight than lithium batteries;
- All materials can be sourced within North America without the need for rare-earth elements.
“Successfully manufacturing our first battery cells is a
pivotal moment in the journey of our battery technology,” said Dennis P.
Calvert, President and CEO of BioLargo. “The testing and validation of these
cells will allow us make claims about the capacity, charge/discharge rate, and other
performance characteristics that we believe differentiate our batteries in the
marketplace. After testing and validation, we will manufacture full-scale prototype
Cellinity battery modules in 25- and 45-kilowatt hour capacities for further testing
and validation.”
He continued, “In parallel to our ongoing development of the
Cellinity battery, we’re exploring various financing options that ensure we get
paid for and are in control of the engineering and construction of
manufacturing facilities. Although initial discussions have taken place, we
have no agreements in place. We believe a licensing and partnership model to be
a better alternative to self-financed and self-operated manufacturing
facilities competing with the likes of Tesla, and well suited for community-based
manufacturing partners focused on underserved communities that are in special
need of reliable renewable energy. Our target projects will add value to
communities, develop workforces, stimulate economic development, promote grid
stability and enable the development and expansion of micro-grids around the
world. We will fundamentally enable and enhance the adoption of renewable energy.”
Mr. Calvert finished by saying, “The world needs a reliable,
safe and eco-friendly alternative to lithium batteries, and we believe our
Cellinity battery will meet these needs.”
About BioLargo, Inc.
BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences
innovator and engineering services solution provider. Our core products address
PFAS contamination, achieve advanced water and wastewater treatment, control
odor and VOCs, improve air quality, enable energy-efficiency and safe on-site
energy storage, and control infections and infectious disease. Our approach is
to invent or acquire novel technologies, develop them into product offerings,
and extend their commercial reach through licensing and channel partnerships to
maximize their impact. See our website at www.BioLargo.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include without limitation those about
BioLargo’s (the “Company”) expectations regarding anticipated revenue; and
plans for future operations. These statements involve risks and uncertainties,
and actual results may differ materially from any future results expressed or
implied by the forward-looking statements. Risks and uncertainties include without
limitation: the effect of regional economic conditions on the Company’s
business, including effects on purchasing decisions by consumers and
businesses; the ability of the Company to compete in markets that are highly
competitive and subject to rapid technological change; the ability of the
Company to manage frequent introductions and transitions of products and
services, including delivering to the marketplace, and stimulating customer
demand for, new products, services, and technological innovations on a timely
basis; the dependency of the Company on the performance of distributors of the
Company’s products. More information on these risks and other potential factors
that could affect the Company’s business and financial results is included in
the Company’s filings with the SEC, including in the “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and Results of
Operations” sections of the Company’s most recently filed periodic reports on
Form 10-K and Form 10-Q and subsequent filings. The Company assumes no
obligation to update any forward-looking statements or information, which speak
as of their respective dates.
Friday 7 June 2024
BioLargo Engineering Secures Multi-Year Air Force Base Air Compliance Project
Westminster, CA – June 7, 2024 – BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that its engineering subsidiary has been awarded a contract to provide air quality services to three New Mexico U.S. Air Force (USAF) bases for up to five years, with a potential annual average revenue of $650,000.
The new contract is in addition to ongoing environmental
support work at six Air Force bases and is the company’s largest dollar-value Air
Force contract to date. These contracts provide regularly monthly flat fee
revenue to the company over the life of the contract, which the Air Force may
renew each year. BioLargo’s work at the New Mexico bases includes air quality
regulatory compliance. Bhate Environmental Associates is the prime contractor
with the Air Force under the Fence-to-Fence (F2F) support contract.
BioLargo Engineering, Science & Technologies President
Randall Moore commented, “Our team has served Air Force bases with
fence-to-fence air quality compliance services for years, but this is the
largest such contract we’ve secured to-date. Larger, long-term contracts such
as this one are crucial to our strategy of securing steady, reliable income
from external clients. This empowers us to focus on commercializing BioLargo’s
innovative cleantech technologies, including advancements in water treatment,
energy storage, and air quality solutions.”
About BioLargo, Inc.
BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences
innovator and engineering services solution provider. Our core products address
PFAS contamination, achieve advanced water and wastewater treatment, control
odor and VOCs, improve air quality, enable energy-efficiency and safe on-site
energy storage, and control infections and infectious disease. Our approach is
to invent or acquire novel technologies, develop them into product offerings,
and extend their commercial reach through licensing and channel partnerships to
maximize their impact. See our website at www.BioLargo.com.
About Bhate Environmental Associates, Inc.
Bhate Environmental Associates, Inc. (Bhate) provides a
diverse range of technical services in the environmental and infrastructure
markets to the federal government and private industry. Headquartered in
Birmingham, Alabama, Bhate’s reach is both national and global. At Bhate, we
value high standards of safety, professionalism, ethics, and service to our
clients. We foster a collaborative environment that encourages innovative ideas
while providing challenges and rewards for our dedicated staff. Through our
team’s Responsiveness, Integrity, and Teamwork, Bhate delivers professional,
quality, cost-effective, and on-time results to our clients. See their website
at www.Bhate.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include without limitation those about
BioLargo’s (the “Company”) expectations regarding anticipated revenue; and
plans for future operations. These statements involve risks and uncertainties,
and actual results may differ materially from any future results expressed or
implied by the forward-looking statements. Risks and uncertainties include without
limitation: the effect of regional economic conditions on the Company’s
business, including effects on purchasing decisions by consumers and
businesses; the ability of the Company to compete in markets that are highly
competitive and subject to rapid technological change; the ability of the
Company to manage frequent introductions and transitions of products and
services, including delivering to the marketplace, and stimulating customer
demand for, new products, services, and technological innovations on a timely
basis; the dependency of the Company on the performance of distributors of the
Company’s products. More information on these risks and other potential factors
that could affect the Company’s business and financial results is included in
the Company’s filings with the SEC, including in the “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and Results of
Operations” sections of the Company’s most recently filed periodic reports on
Form 10-K and Form 10-Q and subsequent filings. The Company assumes no
obligation to update any forward-looking statements or information, which speak
as of their respective dates.
Tuesday 14 May 2024
BioLargo Generates Positive Operating Cash Flow on Record Quarterly Revenues for First Quarter of 2024
Westminster, CA – May 14, 2024 – BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that the company generated $481,000 operating cash flow with record quarterly revenues of $4,760,000 for the three months ended March 31, 2024. The company filed its quarterly report on Form 10-Q with full financial results, available at www.biolargo.com/sec-filings.
BioLargo will hold an investor webcast on Tuesday May 14,
2024, at 2:30 pm Pacific Time, at the following link, open to the public: https://www.webcaster4.com/Webcast/Page/2448/50622
BioLargo’s President and CEO Dennis P. Calvert discussed the
results of the quarter, “We’ve had several years in a row of exceptional revenue
growth, and as a result generated positive cashflow from operations this past
quarter. Our goal, of course, is positive net income, and results like these
bring us closer to achieving that goal.”
He continued, “BioLargo is executing on a winning formula: a
team of highly qualified people dedicated to inventing, proving, and partnering
to capitalize on a diversified portfolio of transformative technologies with
the potential to create real change in the world.”
Financial highlights from the first quarter of 2024:
- Companywide revenue for the three months ended March 31, 2024, grew to $4,760,000, a 9% increase over the fourth quarter of 2023 and a 28% increase over the first quarter of 2023.
- The company generated positive cash from operating activities (cashflow) of $481,000, compared with negative $2,000 in the fourth quarter of 2023.
- The company’s net stockholder’s equity increased from $4.2 million to $5.1 million.
- Net loss was $775,000, a 32% decrease compared to the previous quarter and a 57% increase compared to the same period of 2023. Net loss included $623,000 in non-cash equity compensation expenses.
Business highlights from the first quarter of 2024:
- Launched water equipment subsidiary to capitalize on opportunities in PFAS and water treatment.
- Appointed key industry leaders to board of water equipment subsidiary: Sally Gutierrez, former U.S. EPA Senior Advisor for Water; Jeffrey Kightlinger, recognized water industry leader; and Larry Dick, former Vice Chairman of the board of Metropolitan Water District of Orange County.
- The U.S. EPA finalized two important sets of regulations on PFAS that will influence the growth of the PFAS treatment market and may disproportionately favor our PFAS treatment technology because of its high efficacy against all types of PFAS and its low rate of production of solid PFAS-laden waste as a treatment byproduct.
- Clyra is making substantial investments for scaled-up distribution of its Bioclynse line of products and contracting with third parties for FDA-compliant product manufacturing.
About BioLargo, Inc.
BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences
innovator and engineering services solution provider. Our core products address
PFAS contamination, achieve advanced water and wastewater treatment, control
odor and VOCs, improve air quality, enable energy-efficiency and safe on-site
energy storage, and control infections and infectious disease. Our approach is
to invent or acquire novel technologies, develop them into product offerings,
and extend their commercial reach through licensing and channel partnerships to
maximize their impact. See our website at www.BioLargo.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include without limitation those about
BioLargo’s (the “Company”) expectations regarding anticipated revenue; and
plans for future operations. These statements involve risks and uncertainties,
and actual results may differ materially from any future results expressed or
implied by the forward-looking statements. Risks and uncertainties include without
limitation: the effect of regional economic conditions on the Company’s
business, including effects on purchasing decisions by consumers and
businesses; the ability of the Company to compete in markets that are highly
competitive and subject to rapid technological change; the ability of the
Company to manage frequent introductions and transitions of products and
services, including delivering to the marketplace, and stimulating customer
demand for, new products, services, and technological innovations on a timely
basis; the dependency of the Company on the performance of distributors of the
Company’s products. More information on these risks and other potential factors
that could affect the Company’s business and financial results is included in
the Company’s filings with the SEC, including in the “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and Results of
Operations” sections of the Company’s most recently filed periodic reports on
Form 10-K and Form 10-Q and subsequent filings. The Company assumes no
obligation to update any forward-looking statements or information, which speak
as of their respective dates.